- |||||||||| rasagiline / Generic Mfg.
Review, Journal: Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. (Pubmed Central) - Nov 14, 2019
There are complex interactions between free iron levels in brain and MAO, and cascade of neurotoxic events may have practical outcomes for depressive disorders and neurodegenerative diseases. As consequence recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins, such as BDNF, GDNF VEGF and erythropoietin and induce mitochondrial biogenesis.
- |||||||||| selegiline / generics
Preclinical, Journal: The effect of a neuroprotective dose of isatin or deprenyl to mice on the profile of brain isatin-binding proteins (Pubmed Central) - Nov 14, 2019
In the context of the neuroprotective effect, the effect of isatin is comparable to the effects of deprenyl (selegiline), a pharmacological agent used for treatment of Parkinson's disease...Thus identified brain isatin-binding proteins of the control animals obviously represent specific targets that interact directly with isatin (and also with deprenyl) in vivo. Isatin or deprenyl administered to animals interact with these proteins and thus inhibit their binding to the affinity sorbent (immobilized isatin analogue).
- |||||||||| Zelapar (selegiline orally disintegrating tablets) / Perrigo Company, Amarin, Bausch Health
Journal: Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). (Pubmed Central) - Nov 2, 2019
In addition, molecular dynamics results also revealed that acacetin 7-methyl ether formed a stable and strong complex with MAO-B. The selective inhibition of MAO-B suggests further investigations on acacetin 7-methyl as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease.
- |||||||||| donepezil / Generic mfg., memantine / Generic mfg.
REPURPOSING IGMESINE FOR THE TREA TMENT OF NEURODEGENERATIVE DISEASES. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_311;
Very interesting synergistic e ects were also found with ibuprofen, atorvastatine and selegiline, but not memantine... These encouraging preclinical results prompt us to evaluate the e cacy of igmesine in Phase 2A trials in human.
- |||||||||| selegiline / generics
Clinical outcome in early-treated Sepiapterine Reductase Deficiency (SRD): A case report (Les Muses Terrace, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_592;
At 16 months of age she was able to walk without support; dystonic postures of the upper limbs and gait abnormalities with impaired postural control were observed until the age of 24 months when selegiline was introduced...There are no outcome studies in early-treated SRD patients so far. We confirm the dramatic efficacy of low dosage of biogenic amine precursors on movement disorders in this disease, but also the potential effectiveness of a very early treatment in promoting a normal neurocognitive and neuromotor development.
- |||||||||| selegiline / generics
Preclinical, Journal: Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats. (Pubmed Central) - Sep 14, 2019
This is the first demonstration that selegiline reduces adiposity, alteration in adipose tissue energy metabolism and adipose inflammation induced by HFS diet without affecting the increase in body weight, impairment of glucose homeostasis, or behaviour. These results suggest the potential benefit of selegiline to mitigate harmful effects of visceral adiposity.
- |||||||||| pramipexole IR / generics, selegiline / generics, rasagiline / generics
Preclinical, Journal: Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease. (Pubmed Central) - Aug 22, 2019
In MPTP mice, the antiparkinsonian drug pramipexole (0.3 mg/kg), a DA D and D receptor agonist, that has been shown to be effective in treating depression in PD, ameliorated depression-like behavior and synaptic dysfunction in the mPFC. Taken together, the antidepressant-like effects of selegiline in MPTP mice are attributable to the restoration of impaired synaptic plasticity in the mPFC, suggesting its potential for treating depression in early PD.
- |||||||||| selegiline / generics
Clinical, Journal: Selegiline in Patients With Disorder of Consciousness: An Open Pilot Study. (Pubmed Central) - Jul 19, 2019
After treatment and at 1 month of follow-up, four patients showed improvements in clinical diagnosis, and three patients showed an increase in arousal level only. Selegiline might represent a relatively safe option to enhance arousal and promote recovery in brain-injured patients with disorders of consciousness.
- |||||||||| metformin / generics, sirolimus / generics
Journal: Immunity and longevity. (Pubmed Central) - Jul 7, 2019
It seems likely that there is not a real decline of immunity during aging, but there is a remodeling of the system according to the claims of senescence. This is manifested in the remaining (sometimes stronger) function of memory cells in contrast to the production and number of the new antigen-reactive naive T-cells.
- |||||||||| Valdoxan (agomelatine) / Servier, Novartis, Edronax (reboxetine) / Pfizer, Latuda (lurasidone oral) / Sumitomo Dainippon
Clinical, Review, Journal: The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. (Pubmed Central) - Jun 21, 2019
...The emerging antidepressants are: selective monoamine oxidase inhibitors (MAOIs) such as bifemelane, pirlindole, toloxatone, selegiline, rasagiline and safinamide; serotonin-norepinephrine reuptake inhibitors (SNRIs) such as ansofaxine, nefopam and levomilnacipran; norepinephrine reuptake inhibitors (NRIs) such as Reboxetine, viloxazine, teniloxazine (also known as sulfoxazine or sufoxazine), and atomoxetine; Vilazodone (a serotonin 5-HT autoreceptor partial agonist with serotonin reuptake inhibition [SPARI]); Vortioxetine (a serotonin receptors antagonist with serotonin reuptake inhibition [SARI]); atypical antipsychotics such as olanzapine, quetiapine, risperidone, lurasidone, aripiprazole and brexpiprazole; N-methyl-d-aspartate (NMDA)-glutamatergic neurotransmission system blockers such as ketamine, CP-101,606 (traxoprodil), GLYX-13 (rapastinel), NRX-1074 (Apimostinel) and Riluzole...receptors antagonist [MASSA]) remains a paradoxical agent that doesn't fit into any of the currently available classes of antidepressant agents and its pharmacological properties also deemed it unfit and inappropriate to be classified into another separate novel class of antidepressants contrary to the reports published in previous reference literatures. Lastly, this review remarkably advocates for the incorporation of the atypical antipsychotics and NMDA-glutamatergic ionoceptor blockers as new member classes of the antidepressant agents because of their clinically significant roles in the management of depression disorders.
- |||||||||| rasagiline / generics
Journal: Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis. (Pubmed Central) - Jun 14, 2019
Through decades of research, the literature has accumulated many publications investigating the therapeutic effects of MAO inhibitors (MAOIs) on various neurological conditions, such as Alzheimer's disease (AD), Parkinson's disease (PD), and depression. We envision that MAO literature will continue to grow steadily, with more new therapeutic candidates being tested for better management of neurological conditions, in particular, with the development of multi-target acting drugs against neurodegenerative diseases.
- |||||||||| selegiline / generics, rasagiline / generics
Preclinical, Journal: Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity. (Pubmed Central) - Apr 26, 2019
A single subcutaneous administration of 10 mg/kg selegiline, but not of rasagiline, significantly prevented hippocampal CA1 long-term potentiation impairment, induced by low-frequency stimulation prior to high-frequency stimulation in rats. These results suggest that the antidepressant-like effects of selegiline are attributable to enhancement of dopaminergic transmission and prevention of the impairment of synaptic plasticity in the hippocampus.
- |||||||||| selegiline / generics
Journal: Zebrafish (Danio rerio) Water Tank Model for the Investigation of Drug Metabolism: Progress, Outlook, and Challenges. (Pubmed Central) - Apr 3, 2019
...Sibutramine was applied for the multivariate optimization of ZWT conditions, also for the comparison of the metabolism among ZWT, humans and mice, beyond for the role of CYP2B6 in ZWT...The stereospecificity of the ZWT metabolism was investigated using selegiline and no racemization or inversion transformations were observed...As a result, hexarelin displays a very fast metabolization in ZWT conditions and all the metabolites described for human were observed in ZWT. Therefore, the appropriate conditions, merits and relevant limitations to conduct ZWT experiments for the investigation of drug metabolism were described.
- |||||||||| selegiline / Generic mfg.
Enrollment change: Usefulness of Selegiline as an Aid to Quit Smoking - 1 (clinicaltrials.gov) - Jul 23, 2013
P2, N=101, Completed,
Therefore, the appropriate conditions, merits and relevant limitations to conduct ZWT experiments for the investigation of drug metabolism were described. N=200 --> 101
|
